Effects of sodium valproate on the growth of human ovarian cancer cell line HO8910

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 12, 2012, Pages 6429-6433

  Yan, Hong Chao ^a   Zhang, Jie ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Ovarian cancer; P27; Sodium valproate; Wwox

Indexed keywords

CYCLINE; OXIDOREDUCTASE; P27 ANTIGEN; TUMOR SUPPRESSOR PROTEIN; VALPROIC ACID; WWOX PROTEIN, HUMAN;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CYTOPLASM; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; MOUSE; NUDE MOUSE; OVARY TUMOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOPLASM; FEMALE; G0 PHASE; G1 PHASE; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; OXIDOREDUCTASES; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR SUPPRESSOR PROTEINS; VALPROIC ACID;

EID: 84877081361     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.12.6429     Document Type: Article

References (16)

1. Balakin KV, Ivanenkov YA, Kiselyov AS, et al (2007). Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem, 7, 576-92.
2. Blaheta RA, Nau H, Michaelis M, et al (2002). Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem, 9, 1417-33.
3. Davies AN (2002). Re: Sodium valproate in cancer-related neuropathic pain. J Pain Symptom Manage, 23, 1.
4. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al (2008). Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev, 34, 206-22.
5. Dutertre M, Gratadou L, Dardenne E, et al (2010). Estrogen regulation and physiopathologic significance of alternative promoters in breast cancer. Cancer Res, 70, 3760-70.
6. Fortunati N, Bertino S, Costantino L, et al (2008). Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett, 259, 156-64.
7. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, et al (2007). Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist, 12, 942-51.
8. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
9. Li GF, Qian TL, Li GS, et al (2012). Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression. Genet Mol Res, 11, 77-86.
10. Michaelis M, Doerr HW, Cinatl J, Jr (2007). Valproic acid as anti-cancer drug. Curr Pharm Des, 13, 3378-93.
11. Platta CS, Greenblatt DY, Kunnimalaiyaan M, et al(2008). Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res, 148, 31-7.
12. Sami S, Hoti N, Xu HM, et al (2008). Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem, 144, 357-62.
13. Shi CW, Zhao X, Cao LL, et al (2007). Effect of valproate acid sodium on apoptosis of human gastric cancer cells and its mechanism study. Zhonghua Wei Chang Wai Ke Za Zhi, 10, 468-71.
14. Takai N, Desmond JC, Kumagai T, et al (2004). Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res, 10, 1141-9.
15. Tryfon S, Saroglou M, Kazanas K, et al (2009). Sodium valproate as a cause of recurrent transudative pleural effusion: a case report. J Med Case Rep, 3, 51.
16. Venugopal B, Evans TR (2011). Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem, 18, 1658-71.